J&J is officially cutting the ribbon on its new partnering office in Shanghai, completing the pharma giant's global plan to hit the ground running in all the world's top biotech hot spots. It's taking the wraps off of a lineup of new discovery deals with universities in the region. And it's spreading out feelers for more deals through satellite offices in Australia, Singapore and Japan.
Johnson & Johnson scored a victory in the first case to go to trial for its metal-on-metal hip implants, as a Texas jury ruled against a woman who claimed that Pinnacle devices made by the company's DePuy subsidiary poisoned her and caused undue pain and suffering.
Johnson & Johnson taking its network of biopharma incubators to Texas in an expansion of its Janssen Labs initiative.
Johnson & Johnson is facing grave allegations that the company, in an effort to preserve billions in profit, ignored overwhelming evidence that its Pinnacle hip implants were highly dangerous.
Johnson & Johnson is expanding its network of biopharma incubators, taking to Texas with a plan to host as many as 50 local biotech startups.
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.
With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.
Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
A banner year for Berkeley, CA-based Aduro just got better. The biotech has inked its second licensing pact of the year with Johnson & Johnson, which kicked in a $30 million upfront and boosted its total milestone package to the $1 billion-plus category.
Johnson & Johnson provided a first glimpse of what its devices and diagnostics business will look like after the divestiture of the Ortho Clinical Diagnostics business. The conglomerate gained about $1.1 billion from its sale, which closed on June 30. Excluding the operational impact, the Ortho-Clinical deal boosted sales growth figures for the device and diagnostics unit, as well as the company overall.